The push to contain spiraling health costs around the world could hamper drug makers’ ability to bring new medicines to market, two biopharmaceutical executives warned Wednesday. Marijn Dekkers, chairman of German drug giant Bayer AG, sounded the alarm at a luncheon hosted by the Boston College Chief Executives’ Club of Boston, saying the global economic downturn has intensified pressure to hold down reimbursements for new therapeutics.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help